SUMO2 抗体
Quick Overview for SUMO2 抗体 (ABIN6297478)
抗原
See all SUMO2 抗体适用
宿主
克隆类型
标记
应用范围
-
-
原理
- Mouse anti-Human/Rat SUMO-2 Antibody [Sodium Azide Free]
-
特异性
- Nuclear
-
纯化方法
- Recombinant human protein was used as the immunogen for the SUMO-2 antibody.
-
免疫原
- Recombinant human protein was used as the immunogen for the SUMO-2 antibody.
-
-
-
-
应用备注
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2) -
限制
- 仅限研究用
-
-
-
缓冲液
- In 1X PBS, BSA free, sodium azide free
-
储存液
- Azide free
-
储存条件
- 4 °C,-20 °C
-
储存方法
- 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.
-
-
- SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))
-
别名
- Small ubiquitin-related modifier 2
-
背景
-
Target Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease.
Gene Symbol: SUMO2///SMT3B///SMT3H2
-
基因ID
- 6613
-
UniProt
- P61956
-
途径
- Methionine Biosynthetic Process
抗原
-